According to the latest report by IMARC Group “Digital Dose Inhaler Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027“, The global digital dose inhaler market reached a value of US$ 2.49 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.85 Billion by 2027, exhibiting at a CAGR of 15.1% during 2022-2027.
Digital dose inhalers are used by patients who have asthma and chronic obstructive pulmonary disease (COPD). They have sensors that track the time of medication administration and offer a low-dose warning indicator. Besides this, they have large display screens for easy accessibility and understanding by varied patients. As they are integrated with advanced technology to enable the automatic transfer of data, they are gaining immense traction across the globe.
Request for a free sample copy of this report: https://www.imarcgroup.com/digital-dose-inhaler-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Market Trends:
There is currently a growing prevalence of chronic respiratory diseases (CRDs), such as lung disorders, bronchial asthma, and pulmonary hypertension (PH), which can be accredited to rising pollution levels and occupational dust exposure.This represents one of the key factors positively influencing the demand for digital dose inhalers around the world. Besides this, governing agencies of several countries and non-governmental organizations (NGOs) are spreading awareness about CRDs and available treatments. This is strengthening the growth of the market. The market is further propelled by the introduction of capsule-based and disposable dry powder inhaler (DPI) devices.
Breakup by Type:
- Branded Medication
- Generics Medication
Breakup by Product:
- Metered Dose Inhaler
- Dry Powder Inhaler
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- 3M Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals Limited
- H&T Presspart Manufacturing Ltd.
- Koninklijke Philips N.V.
- Lupin Limited
- Novartis AG
- OPKO Health Inc.
- Propeller Health (ResMed)
- Sensirion AG Switzerland
- Teva Pharmaceutical Industries Ltd.
Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/digital-dose-inhaler-market
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
